Jubilant Pharmova Q2 net profit drops 74.1% to ₹31.2 crore
In short
Jubilant Pharmova reported Q2 FY27 results with net profit falling 74.1% year on year to ₹31.2 crore. Revenue from operations still rose 20.5% to ₹2,370 crore, but EBITDA dropped 29.3% to ₹241 crore.
The company also saw its margin shrink to 10.2% from 17.4%. That means earnings weakened even though sales increased.
What the reporting says
Jubilant Pharmova reported a 74.1% year-on-year fall in consolidated net profit to ₹31.2 crore in Q2 FY27, while revenue from operations rose 20.5% to ₹2,370 crore. EBITDA declined 29.3% to ₹241 crore, and the margin narrowed to 10.2% from 17.4%. The figures point to weaker earnings even as sales grew, driven by lower performance in sterile injectables and radiopharma.
Why it matters
Jubilant Pharmova reported weaker Q2 FY27 earnings, with consolidated net profit falling to ₹31.2 crore even as revenue rose to ₹2,370 crore. EBITDA also declined to ₹241 crore and the margin compressed to 10.2%.